US Capitol Capsule: Paying For Precision Medicine: The Coverage Conundrum
This article was originally published in Scrip
While the science of personalized medicine has been moving at an extremely rapid pace in recent years – evidenced by the fact that 20% of the novel therapies approved by the FDA in 2014 were targeted therapies – the efforts by the biopharmaceutical industry and others in the biomedical community, including the National Institutes of Health (NIH), will all be for naught if payers don't catch up, leaving patients without access, a panel of stakeholders said last week in Washington.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.